TELA Bio (TELA) announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and reconstructive surgery. “The introduction of larger OviTex PRS sizes aligns with evolving trends in plastic and reconstructive surgery and strengthens the breadth of our offering in this space,” said Antony Koblish, Co-founder, President & CEO. “Since launching OviTex PRS in 2019 we have sold nearly 15,000 units, with year-over-year unit sales growth of 31% in 2024 alone. Plastic and reconstructive surgeons are increasingly seeking alternatives to cadaveric tissue, and this expansion reinforces our commitment to meet that demand.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA:
- TELA Bio’s Earnings Call: Challenges and Optimism for 2025
- Tela Bio price target lowered to $6 from $8 at Lake Street, buy on weakness
- Tela Bio price target lowered to $7 from $12 at Canaccord
- Tela Bio price target lowered to $7 from $12 at Citizens JMP
- TELA Bio’s Hold Rating: Challenges in Sales Force Turnover and Financial Outlook